Pharmacogenomics J. 6: 301-310, 2006 –
The promise of drug individualization through pharmacogenomics will be evident initially in those patients who have the poorest therapeutic response or most severe adverse drug effects. In solid-organ transplantation, lung transplantation has the poorest outcome among the commonly transplanted major organs with less than 80% one-year and less than 50% fiveyear survival. Etc.